Shemirani Hassan, Pourrmoghaddas Masood
Department of Cardiology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Saudi J Kidney Dis Transpl. 2012 Mar;23(2):280-5.
Contrast-induced nephropathy (CIN) is characterized by acute deterioration of renal function that occurs after parenteral administration of contrast media in the absence of other causes. Although no definite proof has been obtained yet, the risk of diuretics or angiotensin-converting enzyme inhibitors (ACEI) to exacerbate CIN has been reported because of their effects on renal perfusion. This study was conducted to assess the protective effect of hydration alone in the prevention of CIN after percutaneous coronary intervention (PCI) in patients on diuretics or ACEI. This randomized clinical trial was conducted at the Chamran Hospital, Isfahan University of Medical Sciences, Iran, during the years 2006-2007. The study patients were divided into four groups, each group containing 60 patients. Patients in groups A and B were on regular treatment with ACEI (captopril) and patients in groups C and D were on regular diuretic (furosemide) therapy. About 36 h before PCI, captopril in group A and furosemide in group C were discontinued. The serum creatinine (Cr) levels were measured at the time of performing PCI and 24 h and 48 h after PCI in all patients. All patients received 1 mL/kg/h normal saline (0.9%) 12 h before and 24 h after PCI. The occurrence of CIN after PCI was diagnosed based on the following formula: Cr level after PCI - Cr level before PCI. If this value was greater than 0.5 mg/dL, it was coded as one and if the value was less than 0.5 mg/dL, it was coded as zero. The mean difference was analyzed and compared among the four groups by the ANOVA test. Three patients (5%) in group A, two patients (3.3%) in group B, two patients (3.3%) in group C and one patient (1.6%) in group D had a >0.5 mg/dL difference in serum Cr. The difference seen between these groups was not statistically significant (P > 0.05). This study shows that although furosemide and captopril can exacerbate CIN by impairment of renal perfusion, this can be prevented by hydration and discontinuation of furosemide and captopril may not be required.
对比剂肾病(CIN)的特征是在无其他病因的情况下,经静脉注射造影剂后出现肾功能急性恶化。尽管尚未获得确切证据,但由于利尿剂或血管紧张素转换酶抑制剂(ACEI)对肾灌注的影响,已有报道称其有加重CIN的风险。本研究旨在评估单纯水化对接受利尿剂或ACEI治疗的患者经皮冠状动脉介入治疗(PCI)后预防CIN的保护作用。这项随机临床试验于2006年至2007年在伊朗伊斯法罕医科大学的查姆兰医院进行。研究患者被分为四组,每组60例。A组和B组患者接受常规ACEI(卡托普利)治疗,C组和D组患者接受常规利尿剂(呋塞米)治疗。在PCI前约36小时,停用A组的卡托普利和C组的呋塞米。在所有患者进行PCI时、PCI后24小时和48小时测量血清肌酐(Cr)水平。所有患者在PCI前12小时和PCI后24小时接受1 mL/kg/h的生理盐水(0.9%)。PCI后CIN的发生根据以下公式诊断:PCI后Cr水平 - PCI前Cr水平。如果该值大于0.5 mg/dL,则编码为1;如果该值小于0.5 mg/dL,则编码为0。通过方差分析对四组之间的平均差异进行分析和比较。A组有3例患者(5%)、B组有2例患者(3.3%)、C组有2例患者(3.3%)和D组有1例患者(1.6%)的血清Cr差异>0.5 mg/dL。这些组之间的差异无统计学意义(P>0.05)。本研究表明,尽管呋塞米和卡托普利可通过损害肾灌注加重CIN,但这可通过水化预防,可能无需停用呋塞米和卡托普利。